Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma reported strong full-year FY26 results with consolidated revenue from operations of ₹64,306.50 million, up 14.5% YoY from ₹56,165.04 million. Profit after tax (PAT) more than doubled to ₹14,583.03 million from ₹7,539.13 million, representing a 93.5% PAT growth driven by higher other income and operational efficiency. For Q4 standalone, revenue was ₹17,427.90 million with PAT of ₹4,675.89 million. The auditors (Deloitte Haskins & Sells) issued an unmodified opinion on the annual audited results. An exceptional item of ₹243.46 million was recorded due to additional gratuity and leave liability provisions under new Indian Labour Codes. The Board recommended a final dividend of ₹20 per equity share (2000% on face value of ₹1).
The 93.5% PAT growth and clean audit signal strong operational performance, which should be positive for the stock. The ₹20 dividend reinforces shareholder returns. However, non-controlling interests showed a loss of ₹553.87 million for the year, indicating subsidiary-level challenges.